Bolt Biotherapeutics (NASDAQ:BOLT) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Bolt Biotherapeutics (NASDAQ:BOLT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Bolt Biotherapeutics (NASDAQ:BOLT) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.